HC Wainwright & Co. Maintains Buy on Taro Pharmaceutical Indus, Lowers Price Target to $35
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Taro Pharmaceutical Indus (NYSE:TARO) with a Buy and lowers the price target from $54 to $35.
Taro Pharmaceutical Indus Q3 EPS $0.19 May Not Compare To $0.87 Estimate, Sales $139.20M Miss $163.12M Estimate
Taro Pharmaceutical Indus (NYSE:TARO) reported quarterly earnings of $0.19 per share which missed the analyst consensus estimate of $0.87 by 78.16 percent. This is a 72.86 percent decrease over earnings of $0.70 per
Earnings Scheduled For January 24, 2023
Companies Reporting Before The Bell
• GATX (NYSE:GATX) is expected to report quarterly earnings at $1.44 per share on revenue of $327.63 million.
Taro Pharmaceutical Indus’s Earnings Outlook
Taro Pharmaceutical Indus (NYSE:TARO) is set to give its latest quarterly earnings report on Tuesday, 2023-01-24. Here’s what…
Earnings Scheduled For October 27, 2022
Companies Reporting Before The Bell
• Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.
HC Wainwright & Co. Maintains Buy on Taro Pharmaceutical Indus, Lowers Price Target to $54
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Taro Pharmaceutical Indus (NYSE:TARO) with a Buy and lowers the price target from $73 to $54.
Taro Pharmaceutical Indus: Q1 Earnings Insights
Taro Pharmaceutical Indus (NYSE:TARO) reported its Q1 earnings results on Wednesday, July 27, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Taro Pharmaceutical Indus Q1 EPS $0.37 Down From $1.09 YoY, Sales $156.66M Up From $147.11M YoY
Taro Pharmaceutical Indus (NYSE:TARO) reported quarterly earnings of $0.37 per share. This is a 66.06 percent decrease over earnings of $1.09 per share from the same period last year. The company reported $156.66